Advanced search
Publication Cover
Biomarkers in Medicine Volume 6, 2012 - Issue 1
Submit an article Journal homepage
185
Views
0
CrossRef citations to date
0
Altmetric
Review

Use of Cerebrospinal Fluid Biomarkers in Clinical Trials for Schizophrenia and Depression

Hong I Wan1 Translational Medicine,BioTherapeutics, Pfizer Inc.,South San Francisco,CA94080,USAView further author information
,
Holly Soares2 Clinical Biomarkers,Bristol-Meyers Squibb,Wallingford,CT06492,USAView further author information
&
Jeffrey F Waring3 Translational Sciences,Abbott Laboratories,R4DA, 100 Abbott Park Road,Abbott Park,IL,60064-6123,USA.Correspondence[email protected]
View further author information
Pages 119-129 | Published online: 02 Feb 2012

References

  • DiNunzio JC , WilliamsRO 3rd. CNS disorders – current treatment options and the prospects for advanced therapies. Drug Dev. Ind. Pharm.34(11), 1141–1167 (2008).
  • Flood DG , MarekGJ, WilliamsM. Developing predictive CSF biomarkers: a challenge critical to success in Alzheimer‘s disease and neuropsychiatric translational medicine. Biochem. Pharmacol.81(12), 1422–1234 (2011).
  • Feuerstein GZ , RuffoloRR Jr, StilesG, WalshFS, RutkowskiJL. Translational medicine perspectives of biomarkers in drug discovery and development: part 1 target selection and validation – biomarkers take center stage. Am. Drug Discov.2(5), 36–43 (2007).
  • Feuerstein GZ , DormerC, RuffoloRR Jr, RutkowskiJL, WalshFS, HurkoO. Translational medicine perspectives in drug discovery and development part 2: target compound interaction the vastly neglected biomarkers contributing to early clinical development failure. Am. Drug Discov.3(2), 48–54 (2008).
  • Feuerstein GZ , DormerC, WalshFS, HurkoO, RutkowskiJL. Translational medicine perspectives in drug discovery and development part 3: disease biomarkers, disease modifying biomarkers, disease labeling biomarkers and surrogate biomarkers. Am. Drug Discov.2(4), 36–41 (2008).
  • Tumani H , TeunissenC, SussmuthS, OttoM, LudolphAC, BrettschneiderJ. Cerebrospinal fluid biomarkers of neurodegeneration in chronic neurological diseases. Exp. Rev. Mol. Diagn.8(4), 479–494 (2008).
  • Redzic Z . Molecular biology of the blood–brain and the blood–cerebrospinal fluid barriers: similarities and differences. Fluids Barriers CNS8(1), 3 (2011).
  • Peskind E , NordbergA, Darreh-ShoriT, SoininenH. Safety of lumbar puncture procedures in patients with Alzheimer‘s disease. Curr. Alzheimer Res.6(3), 290–292 (2009).
  • Arendt K , DemaerschalkBM, WingerchukDM, CamannW. Atraumatic lumbar puncture needles: after all these years, are we still missing the point?Neurologist15(1), 17–20 (2009).
  • Blennow K , ZetterbergH. Use of CSF biomarkers in Alzheimer‘s disease clinical trials. J. Nutr. Health Aging13(4), 358–361 (2009).
  • Lewczuk P , BeckG, GanslandtOet al. International quality control survey of neurochemical dementia diagnostics. Neurosci. Lett. 409(1), 1–4 (2006).
  • Craddock RM , HuangJT, JacksonEet al. Increased α-defensins as a blood marker for schizophrenia susceptibility. Mol. Cell Proteomics 7(7), 1204–1213 (2008).
  • Mattsson N . CSF biomarkers in neurodegenerative diseases. Clin. Chem. Lab. Med.49(3), 345–352 (2011).
  • Prvulovic D , HampelH. Amyloid β (Aβ) and phospho-tau (p-tau) as diagnostic biomarkers in Alzheimer‘s disease. Clin. Chem. Lab. Med.49(3), 367–374 (2011).
  • Domenici E , WilleDR, TozziFet al. Plasma protein biomarkers for depression and schizophrenia by multi analyte profiling of case–control collections. PLoS ONE 5(2), e9166 (2010).
  • Takahashi M , HayashiH, WatanabeYet al. Diagnostic classification of schizophrenia by neural network analysis of blood-based gene expression signatures. Schizophr. Res. 119(1–3), 210–218 (2010).
  • Torres KC , SouzaBR, MirandaDMet al. The leukocytes expressing DARPP-32 are reduced in patients with schizophrenia and bipolar disorder. Prog. Neuropsychopharmacol. Biol. Psychiatry 33(2), 214–219 (2009).
  • Blier P , de MontignyC. Antidepressant monoamine oxidase inhibitors enhance serotonin but not norepinephrine neurotransmission. Psychopharmacol. Ser.3, 127–134 (1987).
  • Ross RJ , ZavadilAP 3rd, CalilHMet al. Effects of desmethylimipramine on plasma norepinephrine, pulse, and blood pressure. Clin. Pharmacol. Ther.33(4), 429–437 (1983).
  • Veith RC , LewisN, LinaresOAet al. Sympathetic nervous system activity in major depression. Basal and desipramine-induced alterations in plasma norepinephrine kinetics. Arch. Gen. Psychiatry 51(5), 411–422 (1994).
  • Sharma A , GoldbergMJ, CerimeleBJ. Pharmacokinetics and safety of duloxetine, a dual-serotonin and norepinephrine reuptake inhibitor. J. Clin. Pharmacol.40(2), 161–167 (2000).
  • Wong DT , BymasterFP, MayleDA, ReidLR, KrushinskiJH, RobertsonDW. LY248686, a new inhibitor of serotonin and norepinephrine uptake. Neuropsychopharmacology8(1), 23–33 (1993).
  • Vincent S , BieckPR, GarlandEMet al. Clinical assessment of norepinephrine transporter blockade through biochemical and pharmacological profiles. Circulation 109(25), 3202–3207 (2004).
  • Leibowitz MEL , LinQ, LedentEet al. Use of a biomarker of norepinephrine transporter (NET) inhibition to assess atomoxetine effects during clinically recommended dosing. Presented at: Proceedings of the 18th ECNP Congress. Amsterdam, The Netherlands, 22–26 October 2005.
  • Michelson D , AdlerL, SpencerTet al. Atomoxetine in adults with ADHD: two randomized, placebo-controlled studies. Biol. Psychiatry 53(2), 112–120 (2003).
  • Bymaster FP , KatnerJS, NelsonDLet al. Atomoxetine increases extracellular levels of norepinephrine and dopamine in prefrontal cortex of rat: a potential mechanism for efficacy in attention deficit/hyperactivity disorder. Neuropsychopharmacology 27(5), 699–711 (2002).
  • Gemkow MJ , DavenportAJ, HarichS, EllenbroekBA, CesuraA, HallettD. The histamine H3 receptor as a therapeutic drug target for CNS disorders. Drug Discov. Today14(9–10), 509–515 (2009).
  • Giannoni P , MedhurstAD, PassaniMBet al. Regional differential effects of the novel histamine H3 receptor antagonist 6-[(3-cyclobutyl-2,3,4,5-tetrahydro-1H-3-benzazepin-7-yl)oxy]-N-methyl-3-p yridinecarboxamide hydrochloride (GSK189254) on histamine release in the central nervous system of freely moving rats. J. Pharmacol. Exp. Ther. 332(1), 164–172 (2010).
  • Soares H , WagerT, SchmidtAet al. H3 receptor antagonism increases methylhistamine levels in the cerebrospinal fluid of dogs and healthy human volunteers. Alzheimers Dement. 5(4), 254–255 (2009).
  • Sellin AK , ShadM, TammingaC. Muscarinic agonists for the treatment of cognition in schizophrenia. CNS Spectr.13(11), 985–996 (2008).
  • Nitsch RM , SlackBE, WurtmanRJ, GrowdonJH. Release of Alzheimer amyloid precursor derivatives stimulated by activation of muscarinic acetylcholine receptors. Science258(5080), 304–307 (1992).
  • Fisher A , MichaelsonDM, BrandeisR, HaringR, ChapmanS, PittelZ. M1 muscarinic agonists as potential disease-modifying agents in Alzheimer‘s disease. Rationale and perspectives. Ann. NY Acad. Sci.920, 315–320 (2000).
  • Beach TG , WalkerDG, PotterPE, SueLI, FisherA. Reduction of cerebrospinal fluid amyloid β after systemic administration of M1 muscarinic agonists. Brain Res.905(1–2), 220–223 (2001).
  • Hock C , MaddalenaA, RaschigAet al. Treatment with the selective muscarinic m1 agonist talsaclidine decreases cerebrospinal fluid levels of A β 42 in patients with Alzheimer‘s disease. Amyloid 10(1), 1–6 (2003).
  • Maes M , MeltzerHY, BosmansEet al. Increased plasma concentrations of interleukin-6, soluble interleukin-6, soluble interleukin-2 and transferrin receptor in major depression. J. Affect. Disord. 34(4), 301–309 (1995).
  • Price LH , RasmussenSA. Stress and depression: is neuroimmunology the missing link?Harv. Rev. Psychiat.5(2), 108–112 (1997).
  • Connor TJ , KellyJP, LeonardBE. Forced swim test-induced endocrine and immune changes in the rat: effect of subacute desipramine treatment. Pharmacol. Biochem. Behav.59(1), 171–177 (1998).
  • Maier SF , WatkinsLR. Intracerebroventricular interleukin-1 receptor antagonist blocks the enhancement of fear conditioning and interference with escape produced by inescapable shock. Brain Res.695(2), 279–282 (1995).
  • Asnis GM , De La GarzaR 2nd. Interferon-induced depression in chronic hepatitis C: a review of its prevalence, risk factors, biology, and treatment approaches. J. Clin.Gastroenterol.40(4), 322–335 (2006).
  • Lotrich FE , RabinovitzM, GirondaP, PollockBG. Depression following pegylated interferon-α: characteristics and vulnerability. J. Psychosom. Res.63(2), 131–135 (2007).
  • Malek-Ahmadi P . Cytokines and etiopathogenesis of pervasive developmental disorders. Med. Hypothes.56(3), 321–324 (2001).
  • Levine J , BarakY, ChengappaKN, RapoportA, RebeyM, BarakV. Cerebrospinal cytokine levels in patients with acute depression. Neuropsychobiology40(4), 171–176 (1999).
  • Stubner S , SchonT, PadbergFet al. Interleukin-6 and the soluble IL-6 receptor are decreased in cerebrospinal fluid of geriatric patients with major depression: no alteration of soluble gp130. Neurosci. Lett. 259(3), 145–148 (1999).
  • Carpenter LL , HeningerGR, MalisonRT, TyrkaAR, PriceLH. Cerebrospinal fluid interleukin (IL)-6 in unipolar major depression. J. Affect. Disord.79(1–3), 285–289 (2004).
  • Lindqvist D , JanelidzeS, HagellPet al. Interleukin-6 is elevated in the cerebrospinal fluid of suicide attempters and related to symptom severity. Biol. Psychiat. 66(3), 287–292 (2009).
  • Raison CL , BorisovAS, MajerMet al. Activation of central nervous system inflammatory pathways by interferon-α: relationship to monoamines and depression. Biol. Psychiat. 65(4), 296–303 (2009).
  • Brambilla F , MaggioniM. Blood levels of cytokines in elderly patients with major depressive disorder. Acta Psychiatrica Scand.97(4), 309–313 (1998).
  • Haack M , Hinze-SelchD, FenzelTet al. Plasma levels of cytokines and soluble cytokine receptors in psychiatric patients upon hospital admission: effects of confounding factors and diagnosis. J. Psychiatr. Res. 33(5), 407–418 (1999).
  • Lanquillon S , KriegJC, Bening-Abu-ShachU, VedderH. Cytokine production and treatment response in major depressive disorder. Neuropsychopharmacology22(4), 370–379 (2000).
  • Kubera M , KenisG, BosmansEet al. Plasma levels of interleukin-6, interleukin-10, and interleukin-1 receptor antagonist in depression: comparison between the acute state and after remission. Pol. J. Pharmacol. 52(3), 237–241 (2000).
  • Kagaya A , KugayaA, TakebayashiMet al. Plasma concentrations of interleukin-1β, interleukin-6, soluble interleukin-2 receptor and tumor necrosis factor α of depressed patients in Japan. Neuropsychobiology 43(2), 59–62 (2001).
  • Hirohata S , KanaiY, MitsuoA, TokanoY, HashimotoH. Accuracy of cerebrospinal fluid IL-6 testing for diagnosis of lupus psychosis. A multicenter retrospective study. Clin. Rheumatol.28(11), 1319–1323 (2009).
  • Fragoso-Loyo H , Richaud-PatinY, Orozco-NarvaezAet al. Interleukin-6 and chemokines in the neuropsychiatric manifestations of systemic lupus erythematosus. Arthritis Rheum. 56(4), 1242–1250 (2007).
  • Vila N , ChamorroA, CastilloJ, DavalosA. Glutamate, interleukin-6, and early clinical worsening in patients with acute stroke. Stroke32(5), 1234–1237 (2001).
  • Torre D , ZeroliC, FerraroGet al. Cerebrospinal fluid levels of IL-6 in patients with acute infections of the central nervous system. Scand. J. Infect. Dis. 24(6), 787–791 (1992).
  • Donato R , SorciG, RiuzziFet al. S100B‘s double life: intracellular regulator and extracellular signal. Biochim. Biophys. Acta 1793(6), 1008–1022 (2009).
  • Rothermundt M , FalkaiP, PonathGet al. Glial cell dysfunction in schizophrenia indicated by increased S100B in the CSF. Mol. Psychiatry 9(10), 897–899 (2004).
  • Steiner J , BielauH, BernsteinHG, BogertsB, WunderlichMT. Increased cerebrospinal fluid and serum levels of S100B in first-onset schizophrenia are not related to a degenerative release of glial fibrillar acidic protein, myelin basic protein and neurone-specific enolase from glia or neurones. J. Neurol. Neurosurg. Psychiatry77(11), 1284–1287 (2006).
  • Schwarz E , BahnS. Cerebrospinal fluid: identification of diagnostic markers for schizophrenia. Exp. Rev. Mol. Diagn.8(2), 209–216 (2008).
  • Thompson PM , RosenbergerC, QuallsC. CSF SNAP-25 in schizophrenia and bipolar illness. A pilot study. Neuropsychopharmacology21(6), 717–722 (1999).
  • Kozlovsky N , RegenoldWT, LevineJ, RapoportA, BelmakerRH, AgamG. GSK-3β in cerebrospinal fluid of schizophrenia patients. J. Neural Transm.111(8), 1093–1098 (2004).
  • Li S , WuH, GuoH, ZhaoZ. Neuron-specific enolase and myelin basic protein in cerebrospinal fluid of patients with first episode schizophrenia. J. Huazhong Univ. Sci. Technol. Med. Sci.26(2), 228–230 (2006).
  • Fell MJ , WitkinJM, FalconeJFet al. N-(4-((2-(trifluoromethyl)-3-hydroxy-4-(isobutyryl)phenoxy)methyl)benzyl)- 1-methyl-1H-imidazole-4-carboxamide (THIIC), a novel metabotropic glutamate 2 potentiator with potential anxiolytic/antidepressant properties: in vivo profiling suggests a link between behavioral and central nervous system neurochemical changes. J. Pharmacol. Exp. Ther.336(1), 165–177 (2011).
  • Lowe JA > 3rd, HouX, SchmidtCet al. The discovery of a structurally novel class of inhibitors of the type 1 glycine transporter. Bioorg. Med. Chem. Lett.19(11), 2974–2976 (2009).
  • Huang JT , LewekeFM, OxleyDet al. Disease biomarkers in cerebrospinal fluid of patients with first-onset psychosis. PLoS Med. 3(11), e428 (2006).
  • Huang JT , LewekeFM, TsangTMet al. CSF metabolic and proteomic profiles in patients prodromal for psychosis. PLoS One 2(8), e756 (2007).
  • Craig-Schapiro R , KuhnM, XiongCet al. Multiplexed immunoassay panel identifies novel CSF biomarkers for Alzheimer‘s disease diagnosis and prognosis. PLoS One 6(4), e18850 (2011).
  • Trojanowski JQ , VandeersticheleH, KoreckaMet al. Update on the biomarker core of the Alzheimer‘s Disease Neuroimaging Initiative subjects. Alzheimers Dement. 6(3), 230–238 (2010).
  • Dettmer K , AronovPA, HammockBD. Mass spectrometry-based metabolomics. Mass Spectrom. Rev.26(1), 51–78 (2007).
  • Nicholson JK , LindonJC, HolmesE. ‘Metabonomics‘: understanding the metabolic responses of living systems to pathophysiological stimuli via multivariate statistical analysis of biological NMR spectroscopic data. Xenobiotica29(11), 1181–1189 (1999).
  • Holmes E , TsangTM, HuangJTet al. Metabolic profiling of CSF: evidence that early intervention may impact on disease progression and outcome in schizophrenia. PLoS Med. 3(8), e327 (2006).
  • Ben-Shachar D , LaifenfeldD. Mitochondria, synaptic plasticity, and schizophrenia. Int. Rev. Neurobiol.59, 273–296 (2004).
  • Kato T , KatoN. Mitochondrial dysfunction in bipolar disorder. Bipolar Disord.2(3 Pt 1), 180–190 (2000).
  • Quiroz JA , GrayNA, KatoT, ManjiHK. Mitochondrially mediated plasticity in the pathophysiology and treatment of bipolar disorder. Neuropsychopharmacology33(11), 2551–2565 (2008).
  • Rezin GT , AmboniG, ZugnoAI, QuevedoJ, StreckEL. Mitochondrial dysfunction and psychiatric disorders. Neurochem. Res.34(6), 1021–1029 (2009).
  • Regenold WT , PhatakP, MaranoCM, SassanA, ConleyRR, KlingMA. Elevated cerebrospinal fluid lactate concentrations in patients with bipolar disorder and schizophrenia: implications for the mitochondrial dysfunction hypothesis. Biol. Psychiatry65(6), 489–494 (2009).
  • Simonsen AH , BechS, LaursenIet al. Proteomic investigations of the ventriculo-lumbar gradient in human CSF. J. Neurosci. Methods 191(2), 244–248 (2010).
  • Tarnaris A , TomaAK, ChapmanMDet al. Rostrocaudal dynamics of CSF biomarkers. Neurochem. Res. 36(3), 528–532 (2011).
  • Shaw LM , VandersticheleH, Knapik-CzajkaMet al. Cerebrospinal fluid biomarker signature in Alzheimer‘s disease neuroimaging initiative subjects. Ann.Neurol. 65(4), 403–413 (2009).

Reprints and Corporate Permissions

Please note: Selecting permissions does not provide access to the full text of the article, please see our help page How do I view content?

To request a reprint or corporate permissions for this article, please click on the relevant link below:

Order Reprints Request Corporate Permissions

Academic Permissions

Please note: Selecting permissions does not provide access to the full text of the article, please see our help page How do I view content?

Obtain permissions instantly via Rightslink by clicking on the button below:

Request Academic Permissions

If you are unable to obtain permissions via Rightslink, please complete and submit this Permissions form. For more information, please visit our Permissions help page.

Related research

People also read lists articles that other readers of this article have read.

Recommended articles lists articles that we recommend and is powered by our AI driven recommendation engine.

Cited by lists all citing articles based on Crossref citations.
Articles with the Crossref icon will open in a new tab.